

MucoLox™ in Vaginal Applications

Perhaps the biggest challenge in treating conditions involving vaginal mucosal surfaces is maintaining contact time between the API and vaginal mucosa in spite of secretions.

Our PCCA exclusive base, MucoLox, was specifically designed to help compounders overcome these challenges. It provides long-lasting coverage and has a lightweight coating effect that is water-washable, so it stays on unless you don't want it to. MucoLox creates an ionic bond with the mucous membrane, allowing for adhesion up to 24 times longer than other products.¹ And that bond makes all the difference – expanding the contact time between API and target area.

DOSAGE FORMS

- Vaginal suppositories
- Vaginal creams
- Vaginal gels

FORMULATIONS FOR WOMEN'S HEALTH INCLUDE

- Hormone replacement therapy
- Vaginal infections
- Vaginal dryness
- Vaginal lesions
- Vaginal pain

BENEFITS

- Water soluble for improved moisturization
- Ionic attraction creates bond with the mucous membrane
- Won't easily wash away with vaginal discharge or other mucosal secretions
- Increases contact time with mucosa and API
- Provides coverage for long-lasting protection
- Formulated without gluten, casein, dye and parabens, among other allergens

PROOF

1. PCCA Document #98928 – Technical Report: Assessment of the Mucoadhesive Properties of MucoLox Using a 3D Model of the Human Oral Mucosa

Abstract: In a study using a 3-D model of the human oral mucosa, MucoLox adhered to the site 24 times longer than a commercial reference product. That means the potential for better delivery of active ingredients at the desired site of action.

2. PCCA Document #98930 – Technical Report: Evaluation of the Safety and Toxicological Profile of MucoLox: Human Oral Mucosa, Nasal Mucosa and Vaginal Mucosa (Part 3/3)*

Abstract: In a study evaluating the toxicity to tissue over time, MucoLox was minimally toxic to vaginal mucosa over a period of 20 hours of exposure. This shows that compounded medicines prepared with MucoLox can remain at the site of action for longer periods of time without irritation, thus potentially maximizing the effectiveness of each administration and reducing the frequency of dosing.

* See PCCA Document #98929 for part one of this study, which addresses human oral mucosa, and PCCA Document #98933 for part two of this study, which addresses nasal mucosa.

For questions about MucoLox formulas and applications, please contact our Pharmacy Consulting Department at [800.331.2498](tel:800.331.2498).

REFERENCES

- ¹ PCCA Science. (2015). Technical Report: Assessment of Mucoadhesive Properties of MucoLox™ Using 3D Model of the Human Oral Mucosa. PCCA Document #98928.

Now Available – New FREE vaginal marketing materials!

Available for download on the Members-Only Website under Products > MucoLox, then go to the Marketing tab.

These statements have not been evaluated by the Food and Drug Administration. Every effort has been made to accurately represent scientific research that utilized PCCA products. Results of studies or case reports in these materials are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information is provided for educational purposes only. It is not intended to replace or substitute for conventional medical care, or encourage its abandonment. ©